- Home
- ERAS vs NFJ Comparison
ERAS vs NFJ Comparison
Compare ERAS & NFJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ERAS | NFJ |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ERAS | NFJ |
|---|---|---|
| Price | $3.44 | $12.89 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $3.71 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 223.5K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.01% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $10.45 |
| 52 Week High | $3.80 | $12.86 |
Technical Indicators
Market Signals| Indicator | ERAS | NFJ |
|---|---|---|
| Relative Strength Index (RSI) | 55.97 | 50.99 |
| Support Level | $3.36 | $12.58 |
| Resistance Level | $3.77 | $12.92 |
| Average True Range (ATR) | 0.24 | 0.12 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 40.77 | 43.66 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.